Logo

UNCY

Unicycive Therapeutics, Inc.

UNCY

Unicycive Therapeutics, Inc. • NASDAQ
$6.47 ▲ 2.70% (+0.17)
Market Cap $114.27 M
52w High $11.00
52w Low $3.71
Dividend Yield 0%
P/E -1.88
Volume 336.15K
Outstanding Shares 17.66M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.342M ▲ $-6.011M ▲ 0% $-0.33 ▲ $-5.848M ▲
Q2-2025 $0 $6.963M ▼ $-6.447M ▼ 0% $-0.52 ▼ $-6.296M ▼
Q1-2025 $0 $7.989M ▼ $570K ▲ 0% $0.044 ▲ $720K ▲
Q4-2024 $0 $9.261M ▲ $-21.525M ▼ 0% $-2 ▼ $-9.254M ▼
Q3-2024 $0 $6.251M $-4.096M 0% $-0.46 $-3.958M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $42.695M ▲ $50.611M ▲ $13.131M ▼ $37.48M ▲
Q2-2025 $22.327M ▲ $29.995M ▲ $13.566M ▼ $16.429M ▲
Q1-2025 $19.769M ▼ $27.947M ▼ $16.676M ▼ $11.271M ▲
Q4-2024 $26.142M ▼ $31.668M ▼ $24.237M ▲ $7.431M ▼
Q3-2024 $32.347M $38.574M $10.724M $27.85M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.011M ▲ $-5.962M ▲ $-2K ▲ $26.332M ▲ $20.368M ▲ $-5.964M ▲
Q2-2025 $-6.447M ▼ $-8.42M ▲ $-6K ▲ $10.984M ▲ $2.558M ▲ $-8.426M ▲
Q1-2025 $570K ▲ $-8.903M ▼ $-16K ▲ $2.546M ▲ $-6.373M ▼ $-8.919M ▼
Q4-2024 $-21.525M ▼ $-6.548M ▲ $-22K ▲ $365K ▲ $-6.205M ▲ $-6.57M ▲
Q3-2024 $-4.096M $-9.252M $-24K $-157K $-9.433M $-9.276M

Five-Year Company Overview

Income Statement

Income Statement The company is still firmly in the development stage, with essentially no product revenue so far. The income statement is driven almost entirely by research and development and other operating expenses, which result in steady losses each year. Those losses have grown over time as the pipeline has advanced and spending has increased, which is common for a clinical‑stage biotech. The very sharp change in earnings per share mainly reflects share count and capital structure changes, not a sudden shift in the underlying business. Overall, the financial story today is one of investment and cash burn rather than profit generation.

Balance Sheet

Balance Sheet The balance sheet is small but relatively simple. Assets are mostly cash, with very little in the way of physical assets or long‑lived equipment, which fits an asset‑light biotech model. There is no financial debt reported, which removes interest‑burden risk but also means the company largely relies on equity and possibly partnerships for funding. Shareholders’ equity is positive but thin, reflecting cumulative losses over time. The reported cash runway into the latter part of the decade suggests they are reasonably funded for current plans, but the balance sheet will remain sensitive to trial outcomes, regulatory milestones, and future capital raises.

Cash Flow

Cash Flow Cash flows are negative and closely track operating losses, as expected for a pre‑revenue biotech. Operating cash outflows are driven by clinical trials, regulatory work, and overhead, with essentially no offsetting inflows from product sales. Capital spending is minimal, so free cash flow is largely the same as operating cash flow, reinforcing that this is an R&D‑driven, not capital‑intensive, business. The company’s ability to sustain these outflows depends on its existing cash, potential future financings, and any non‑dilutive sources such as partnerships or milestone payments it may secure. Until commercialization, investors should expect continued cash burn rather than self‑funding operations.

Competitive Edge

Competitive Edge Unicycive is focusing on kidney disease, a specialized and sizable niche within healthcare. Its lead candidate, OLC, aims to solve a very practical problem in dialysis patients: many existing phosphate binders require large, frequent pills that patients often dislike and skip. By using nanoparticle technology to shrink pill size and cut pill burden, OLC targets patient convenience and adherence as its main edge versus established drugs. The company backs this with a solid patent portfolio, which can help protect its position if the drug reaches the market. Its second asset, UNI‑494, goes after acute kidney injury, an area with no approved targeted therapies, which could be a large opportunity but also carries substantial scientific and regulatory risk. Competition remains meaningful: OLC would enter a market with entrenched products and large players, and UNI‑494 competes against ongoing efforts in academia and industry to address kidney injury. Overall, the company has a clear niche and differentiated story, but its competitive strength will ultimately depend on regulatory success, payer acceptance, and its ability to execute commercialization in a concentrated dialysis market.

Innovation and R&D

Innovation and R&D Innovation is the core of Unicycive’s value proposition. OLC uses a novel formulation approach to make an existing mechanism more patient‑friendly, seeking to win on convenience and adherence rather than purely on a new biology. Clinical data suggesting strong patient preference and much lower pill burden support this positioning, and the use of an expedited regulatory pathway can shorten timelines if all goes well. UNI‑494 represents a more transformative, higher‑risk program: a first‑in‑class mitochondrial‑targeted therapy for acute kidney injury. Its orphan designation in a transplant‑related indication offers potential regulatory and commercial benefits, including possible exclusivity if approved. At the same time, the pipeline is concentrated, so scientific or regulatory setbacks in either of the two lead programs would materially affect the company. Planned milestones such as the OLC resubmission and progression of UNI‑494 into mid‑stage trials are key inflection points for assessing how well the innovation story is translating into clinical and regulatory progress.

Summary

Unicycive is a young, clinical‑stage biotech fully in its investment phase: no revenue yet, ongoing operating losses, and consistent cash burn, but with a focused balance sheet and no debt. The financial picture is typical for this stage and means the company’s future hinges on trial results, regulatory decisions, and access to capital. Strategically, it is narrowly focused on kidney disease, with one late‑stage asset (OLC) that seeks to improve a well‑known pain point in dialysis care—pill burden—and one earlier‑stage, higher‑risk asset (UNI‑494) that aims to break new ground in acute kidney injury. Strong intellectual property, use of streamlined regulatory pathways, and a lean development model are positives. Key risks include the all‑or‑nothing nature of key regulatory events, concentrated dependence on a small pipeline, competition from established nephrology products, and the eventual challenge of commercializing into a market dominated by large dialysis organizations. Overall, Unicycive’s profile is that of a focused, innovation‑driven biotech with meaningful upside if its programs succeed and typical clinical‑stage risks if they do not. Its financial health appears adequate for near‑term plans, but long‑term outcomes remain highly dependent on clinical, regulatory, and commercial execution.

NEWS

November 25, 2025 · 7:05 AM UTC

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

Read more

November 12, 2025 · 7:05 AM UTC

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 3, 2025 · 7:05 AM UTC

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Read more

October 31, 2025 · 12:05 PM UTC

UNICYCIVE ALERT: Bragar Eagel & Squire, P.C. is Investigating Unicycive Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Read more

October 30, 2025 · 7:05 AM UTC

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

Read more